BioAtla granted Nasdaq continued listing with conditions through Feb 2026

BioAtla, Inc.

Nasdaq Panel approved continued listing pending transfer to Capital Market by Sept 26, 2025 (filed Sept 18).
Must demonstrate compliance with Minimum Stockholders' Equity Requirement by Dec 31, 2025.
Must demonstrate compliance with Minimum Bid Price Requirement by Feb 2, 2026.
Company believes it can meet both deadlines but provides no assurance.
Previously disclosed delisting risk from failure to meet bid price and equity requirements.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.